Status:
COMPLETED
Efficacy and Economic Evaluation of Nonbiological Artificial Liver Therapy in Acute-on-chronic Hepatitis B Liver Failure.
Lead Sponsor:
Xiangya Hospital of Central South University
Conditions:
Chronic-on-acute Liver Failure
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This was a non-blinded, prospective clinical study. From June 2020 to October 2021, 254 patients with HBV-ACLF were treated at the Department of Infectious Diseases, Xiangya Hospital, Central South Un...
Eligibility Criteria
Inclusion
- aged 18-65 years old
- patients with ACLF caused by HBV infection
- meeting the diagnostic criteria for ACLF by the Asian Pacific Association for the Study of Liver.
Exclusion
- pregnancy or lactation
- previous liver transplantation
- hepatocellular carcinoma or other malignancy
- human immunodeficiency virus(HIV) infection or other immunocompromised state
- complicated with underlying diseases such as severe heart, respiratory, and blood system diseases
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2021
Estimated Enrollment :
186 Patients enrolled
Trial Details
Trial ID
NCT05392673
Start Date
June 1 2020
End Date
October 31 2021
Last Update
May 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xiangya Hospital of Central South University
Changsha, China